

Activity Outline
FDA Grand Rounds: Laboratory and Clinical Studies to Investigate Whether Ranitidine Converts to a Probable Carcinogen in Humans
October 14, 2021
Virtual: Adobe platform

Activity Coordinator:

Madison Hanson (Madison.Hanson@fda.hhs.gov), Rokhsareh Shahidzadeh (rokhsareh.shahidzadeh@fda.hhs.gov),
Sharron Watson (Sharron.Watson@fda.hhs.gov),

Series Description

The FDA Grand Rounds is webcast every other month to highlight cutting-edge research underway across the agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities.

Lecture Description

CDER researchers conducted and published clinical and nonclinical studies in response to concerns whether ranitidine converts to the probable human carcinogen N-nitrosodimethylamine (NDMA) in humans. This research found no evidence of elevated NDMA content in urine or blood when participants consumed ranitidine and showed that ranitidine does not convert to NDMA in vitro studies under physiologic gastric nitrite concentrations.

References

- Florian J, MK Murali, R DePalma, et al, Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA): A Randomized Clinical Trial, JAMA, 2021;326(3):240-9, doi:10.1001/jama.2021.9199.
- Gao Z, M Karfunkle, Y Wei Ye, et al, In Vitro Analysis of N-Nitrosodimethylamine (NDMA) Formation From Ranitidine Under Simulated Gastrointestinal Conditions, JAMA Netw Open, 2021;4(6):e2118253, doi:10.1001/jamanetworkopen.2021.18253.
- Florian J, MK Murali, R DePalma, et al, Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA): A Randomized Clinical Trial, JAMA, 2021;326(3):240-9, doi:10.1001/jama.2021.9199.
- Gao Z, M Karfunkle, Y Wei Ye, et al, In Vitro Analysis of N-Nitrosodimethylamine (NDMA) Formation From Ranitidine Under Simulated Gastrointestinal Conditions, JAMA Netw Open, 2021;4(6):e2118253, doi:10.1001/jamanetworkopen.2021.18253.
- Gao Z, M Karfunkle, Y Wei Ye, et al, In Vitro Analysis of N-Nitrosodimethylamine (NDMA) Formation From Ranitidine Under Simulated Gastrointestinal Conditions, JAMA Netw Open, 2021;4(6):e2118253, doi:10.1001/jamanetworkopen.2021.18253.
- Florian J, MK Murali, R DePalma, et al, Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA): A Randomized Clinical Trial, JAMA, 2021;326(3):240-9, doi:10.1001/jama.2021.9199.
- Florian J, MK Murali, R DePalma, et al, Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA): A Randomized Clinical Trial, JAMA, 2021;326(3):240-9, doi:10.1001/jama.2021.9199.

Series Objectives

- Discuss the research conducted at the FDA
- Explain how FDA science impacts public health

Learning Objectives After completion of this activity, the participant will be able to:

- Describe how the FDA investigated and responded to NDMA impurities in ranitidine products.
- Discuss results from a clinical study and in vitro investigations initiated by the FDA that refute concerns that ranitidine is converted to NDMA in humans.
- Explain how the Center for Drug Evaluation Research's capabilities and activities empower the agency to respond rapidly to emergent regulatory and public health questions regarding the products it regulates.

Target Audience

This activity is intended for physicians, pharmacists, nurses, and other scientists within the agency external scientific communities.

Agenda

Lecture 1 October 14, 2021

Time	Topic	Speaker
12:00 - 1:00 PM	Laboratory and Clinical Studies to Investigate Whether Ranitidine Converts to a Probable Carcinogen in Humans	David Keire Jeffry Florian, PhD

Continuing Education Accreditation



In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-21-016-L04-P for 1.00 contact hour(s).

CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

Requirements for Receiving CE Credit

Physicians, pharmacists, nurses, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.

Important Note regarding completion of evaluations and receiving credit

Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.

Disclosure

Faculty

- ▣ Florian, Jeffry, PhD, General Health Scientist, US Food and Drug Administration *nothing to disclose*
- ▣ Keire, David, Division Director, OPQ/OTR *My spouse received Salary from Bayer Crop Sciences for a role as Employee.*

Planning Committee

- ▣ Dinatale, Miriam, Team Leader, Food and Drug Administration *nothing to disclose*
- ▣ Pfundt, Tiffany, PharmD, Pharmacist, FDA *nothing to disclose*
- ▣ Wheelock, Leslie, RN, MS, Director, OSPD, FDA, OC, OCS, OSPD *nothing to disclose*

CE Consultation and Accreditation Team

- ▣ Bryant, Traci, M.A.T., CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- ▣ Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose

Registration Fee and Refunds

Registration is complimentary, therefore refunds are not applicable.